Interventions in Wnt signaling as a novel therapeutic approach to improve myocardial infarct healing

Fibrogenesis & Tissue Repair

W Matthijs Blankesteijn¹  Evangelos P Daskalopoulos¹  Kevin CM Hermans¹ 

[1] Department of Pharmacology, Cardiovascular Research Institute Maastricht, Maastricht University, 50 Universiteitssingel, 6229ER Maastricht, PO Box 616 6200MD, Maastricht, The Netherlands

关键词: Cardiac remodeling;    Wound healing;    Stem cells;    Neovascularization;    Myofibroblast;    Frizzled;    Wnt;    Myocardial infarction;   

Others  :  803551
DOI  :  10.1186/1755-1536-5-16

 received in 2012-07-04, accepted in 2012-08-20,  发布年份 2012

【 摘 要 】

Following myocardial infarction, wound healing takes place in the infarct area where the non-viable cardiac tissue is replaced by a scar. Inadequate wound healing or insufficient maintenance of the extracellular matrix in the scar can lead to excessive dilatation of the ventricles, one of the hallmarks of congestive heart failure. Therefore, it is important to better understand the wound-healing process in the heart and to develop new therapeutic agents that target the infarct area in order to maintain an adequate cardiac function. One of these potential novel therapeutic targets is Wnt signaling. Wnt signaling plays an important role in embryonic myocardial development but in the adult heart the pathway is thought to be silent. However, there is increasing evidence that components of the Wnt pathway are re-expressed during cardiac repair, implying a regulatory role. Recently, several studies have been published where the effect of interventions in Wnt signaling on infarct healing has been studied. In this review, we will summarize the results of these studies and discuss the effects of these interventions on the different cell types that are involved in the wound healing process.

【 授权许可】

   
2012 Hermans et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Cardiovascular diseases (CVDs): WHO Fact Sheet N°317. http://www.who.int/mediacentre/factsheets/fs317/en/
• [2]Cleutjens JP, Blankesteijn WM, Daemen MJ, Smits JF: The infarcted myocardium: simply dead tissue, or a lively target for therapeutic interventions. Cardiovasc Res 1999, 44:232-241.
• [3]Rossen RD, Michael LH, Kagiyama A, Savage HE, Hanson G, Reisberg MA, Moake JN, Kim SH, Self D, Weakley S: Mechanism of complement activation after coronary artery occlusion: evidence that myocardial ischemia in dogs causes release of constituents of myocardial subcellular origin that complex with human C1q in vivo. Circ Res 1988, 62:572-584.
• [4]Jordan JE, Zhao ZQ, Vinten-Johansen J: The role of neutrophils in myocardial ischemia-reperfusion injury. Cardiovasc Res 1999, 43:860-878.
• [5]Nahrendorf M, Pittet MJ, Swirski FK: Monocytes: protagonists of infarct inflammation and repair after myocardial infarction. Circulation 2010, 121:2437-2445.
• [6]Dobaczewski M, Chen W, Frangogiannis NG: Transforming growth factor (TGF)-beta signaling in cardiac remodeling. J Mol Cell Cardiol 2011, 51:600-606.
• [7]Rosenkranz S: TGF-beta1 and angiotensin networking in cardiac remodeling. Cardiovasc Res 2004, 63:423-432.
• [8]Bishop JE, Laurent GJ: Collagen turnover and its regulation in the normal and hypertrophying heart. Eur Heart J 1995, Suppl C:38-44.
• [9]van der Laan AM, Piek JJ, van Royen N: Targeting angiogenesis to restore the microcirculation after reperfused MI. Nat Rev Cardiol 2009, 6:515-523.
• [10]Jugdutt BI: Ventricular remodeling after infarction and the extracellular collagen matrix: when is enough enough? Circulation 2003, 108:1395-1403.
• [11]Bujak M, Ren G, Kweon HJ, Dobaczewski M, Reddy A, Taffet G, Wang XF, Frangogiannis NG: Essential role of Smad3 in infarct healing and in the pathogenesis of cardiac remodeling. Circulation 2007, 116:2127-2138.
• [12]van den Borne SW, Diez J, Blankesteijn WM, Verjans J, Hofstra L, Narula J: Myocardial remodeling after infarction: the role of myofibroblasts. Nat Rev Cardiol 2010, 7:30-37.
• [13]Logan CY, Nusse R: The Wnt signaling pathway in development and disease. Annu Rev Cell Dev Biol 2004, 20:781-810.
• [14]MacDonald BT, Tamai K, He X: Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev Cell 2009, 17:9-26.
• [15]Eisenberg LM, Eisenberg CA: Evaluating the role of Wnt signal transduction in promoting the development of the heart. Sci World J 2007, 7:161-176.
• [16]Brade T, Manner J, Kuhl M: The role of Wnt signalling in cardiac development and tissue remodelling in the mature heart. Cardiovasc Res 2006, 72:198-209.
• [17]Tzahor E: Wnt/beta-catenin signaling and cardiogenesis: timing does matter. Dev Cell 2007, 13:10-13.
• [18]Kuwahara K, Nakao K: New molecular mechanisms for cardiovascular disease: transcriptional pathways and novel therapeutic targets in heart failure. J Pharmacol Sci 2011, 116:337-342.
• [19]Oerlemans MI, Goumans MJ, van Middelaar B, Clevers H, Doevendans PA, Sluijter JP: Active Wnt signaling in response to cardiac injury. Basic Res Cardiol 2010, 105:631-641.
• [20]Duan J, Gherghe C, Liu D, Hamlett E, Srikantha L, Rodgers L, Regan JN, Rojas M, Willis M, Leask A, Majesky M, Deb A: Wnt1/betacatenin injury response activates the epicardium and cardiac fibroblasts to promote cardiac repair. Embo J 2012, 31:429-442.
• [21]Aisagbonhi O, Rai M, Ryzhov S, Atria N, Feoktistov I, Hatzopoulos AK: Experimental myocardial infarction triggers canonical Wnt signaling and endothelial-to-mesenchymal transition. Dis Model Mech 2011, 4:469-483.
• [22]Chen L, Wu Q, Guo F, Xia B, Zuo J: Expression of Dishevelled-1 in wound healing after acute myocardial infarction: possible involvement in myofibroblast proliferation and migration. J Cell Mol Med 2004, 8:257-264.
• [23]Barandon L, Couffinhal T, Ezan J, Dufourcq P, Costet P, Alzieu P, Leroux L, Moreau C, Dare D, Duplaa C: Reduction of infarct size and prevention of cardiac rupture in transgenic mice overexpressing FrzA. Circulation 2003, 108:2282-2289.
• [24]Mikels AJ, Nusse R: Wnts as ligands: processing, secretion and reception. Oncogene 2006, 25:7461-7468.
• [25]Kikuchi A, Yamamoto H, Kishida S: Multiplicity of the interactions of Wnt proteins and their receptors. Cell Signal 2007, 19:659-671.
• [26]Povelones M, Nusse R: The role of the cysteine-rich domain of Frizzled in Wingless-Armadillo signaling. Embo J 2005, 24:3493-3503.
• [27]Mi K, Johnson GV: Role of the intracellular domains of LRP5 and LRP6 in activating the Wnt canonical pathway. J Cell Biochem 2005, 95:328-338.
• [28]Kawano Y, Kypta R: Secreted antagonists of the Wnt signalling pathway. J Cell Sci 2003, 116:2627-2634.
• [29]Krishnan V, Bryant HU, Macdougald OA: Regulation of bone mass by Wnt signaling. J Clin Invest 2006, 116:1202-1209.
• [30]Kikuchi A: Regulation of beta-catenin signaling in the Wnt pathway. Biochem Biophys Res Commun 2000, 268:243-248.
• [31]Dang CV: c-myc target genes involved in cell growth, apoptosis, and metabolism. Mol Cell Biol 1999, 19:1-11.
• [32]Hilberg F, Wagner EF: Embryonic stem (ES) cells lacking functional c-jun: consequences for growth and differentiation, AP-1 activity and tumorigenicity. Oncogene 1992, 7:2371-2380.
• [33]Adiseshaiah P, Vaz M, Machireddy N, Kalvakolanu DV, Reddy SP: A Fra-1-dependent, matrix metalloproteinase driven EGFR activation promotes human lung epithelial cell motility and invasion. J Cell Physiol 2008, 216:405-412.
• [34]Takahashi-Yanaga F, Sasaguri T: GSK-3beta regulates cyclin D1 expression: a new target for chemotherapy. Cell Signal 2008, 20:581-589.
• [35]Rao TP, Kuhl M: An updated overview on Wnt signaling pathways: a prelude for more. Circ Res 2010, 106:1798-1806.
• [36]van Amerongen R, Mikels A, Nusse R: Alternative Wnt signaling is initiated by distinct receptors. Sci Signal 2008, 1:re9.
• [37]Manabe I, Shindo T, Nagai R: Gene expression in fibroblasts and fibrosis: involvement in cardiac hypertrophy. Circ Res 2002, 91:1103-1113.
• [38]Souders CA, Bowers SL, Baudino TA: Cardiac fibroblast: the renaissance cell. Circ Res 2009, 105:1164-1176.
• [39]Tomasek JJ, Gabbiani G, Hinz B, Chaponnier C, Brown RA: Myofibroblasts and mechano-regulation of connective tissue remodelling. Nat Rev Mol Cell Biol 2002, 3:349-363.
• [40]Gabbiani G: Evolution and clinical implications of the myofibroblast concept. Cardiovasc Res 1998, 38:545-548.
• [41]Petrov VV, Fagard RH, Lijnen PJ: Stimulation of collagen production by transforming growth factor-beta1 during differentiation of cardiac fibroblasts to myofibroblasts. Hypertension 2002, 39:258-263.
• [42]Sun Y, Weber KT: Angiotensin converting enzyme and myofibroblasts during tissue repair in the rat heart. J Mol Cell Cardiol 1996, 28:851-858.
• [43]Zhou B, Pu WT: Epicardial epithelial-to-mesenchymal transition in injured heart. J Cell Mol Med 2011, 15:2781-2783.
• [44]Zeisberg EM, Tarnavski O, Zeisberg M, Dorfman AL, McMullen JR, Gustafsson E, Chandraker A, Yuan X, Pu WT, Roberts AB, Neilson EG, Sayegh MH, Izumo S, Kalluri R: Endothelial-to-mesenchymal transition contributes to cardiac fibrosis. Nat Med 2007, 13:952-961.
• [45]van Amerongen MJ, Bou-Gharios G, Popa E, van Ark J, Petersen AH, van Dam GM, van Luyn MJ, Harmsen MC: Bone marrow-derived myofibroblasts contribute functionally to scar formation after myocardial infarction. J Pathol 2008, 214:377-386.
• [46]Mollmann H, Nef HM, Kostin S, von Kalle C, Pilz I, Weber M, Schaper J, Hamm CW, Elsasser A: Bone marrow-derived cells contribute to infarct remodelling. Cardiovasc Res 2006, 71:661-671.
• [47]Haudek SB, Xia Y, Huebener P, Lee JM, Carlson S, Crawford JR, Pilling D, Gomer RH, Trial J, Frangogiannis NG, Entman ML: Bone marrow-derived fibroblast precursors mediate ischemic cardiomyopathy in mice. Proc Natl Acad Sci USA 2006, 103:18284-18289.
• [48]Fujita J, Mori M, Kawada H, Ieda Y, Tsuma M, Matsuzaki Y, Kawaguchi H, Yagi T, Yuasa S, Endo J, Hotta T, Ogawa S, Okano H, Yozu R, Ando K, Fukuda K: Administration of granulocyte colony-stimulating factor after myocardial infarction enhances the recruitment of hematopoietic stem cell-derived myofibroblasts and contributes to cardiac repair. Stem Cells 2007, 25:2750-2759.
• [49]Endo J, Sano M, Fujita J, Hayashida K, Yuasa S, Aoyama N, Takehara Y, Kato O, Makino S, Ogawa S, Fukuda K: Bone marrow derived cells are involved in the pathogenesis of cardiac hypertrophy in response to pressure overload. Circulation 2007, 116:1176-1184.
• [50]Blankesteijn WM, Essers-Janssen YP, Verluyten MJ, Daemen MJ, Smits JF: A homologue of Drosophila tissue polarity gene frizzled is expressed in migrating myofibroblasts in the infarcted rat heart. Nat Med 1997, 3:541-544.
• [51]Carthy JM, Garmaroudi FS, Luo Z, McManus BM: Wnt3a induces myofibroblast differentiation by upregulating TGF-beta signaling through SMAD2 in a beta-catenin-dependent manner. PLoS One 2011, 6:e19809.
• [52]Hahn JY, Cho HJ, Bae JW, Yuk HS, Kim KI, Park KW, Koo BK, Chae IH, Shin CS, Oh BH, Choi YS, Park YB, Kim HS: Beta-catenin overexpression reduces myocardial infarct size through differential effects on cardiomyocytes and cardiac fibroblasts. J Biol Chem 2006, 281:30979-30989.
• [53]Laeremans H, Rensen SS, Ottenheijm HC, Smits JF, Blankesteijn WM: Wnt/frizzled signalling modulates the migration and differentiation of immortalized cardiac fibroblasts. Cardiovasc Res 2010, 87:514-523.
• [54]He W, Zhang L, Ni A, Zhang Z, Mirotsou M, Mao L, Pratt RE, Dzau VJ: Exogenously administered secreted frizzled related protein 2 (Sfrp2) reduces fibrosis and improves cardiac function in a rat model of myocardial infarction. Proc Natl Acad Sci USA 2010, 107:21110-21115.
• [55]Barandon L, Couffinhal T, Dufourcq P, Ezan J, Costet P, Daret D, Deville C, Duplaa C: Frizzled A, a novel angiogenic factor: promises for cardiac repair. Eur J Cardiothorac Surg 2004, 25:76-83.
• [56]Barandon L, Casassus F, Leroux L, Moreau C, Allieres C, Lamaziere JM, Dufourcq P, Couffinhal T, Duplaa C: Secreted frizzled-related protein-1 improves postinfarction scar formation through a modulation of inflammatory response. Arterioscler Thromb Vasc Biol 2011, 31:e80-e87.
• [57]Hayashidani S, Tsutsui H, Ikeuchi M, Shiomi T, Matsusaka H, Kubota T, Imanaka-Yoshida K, Itoh T, Takeshita A: Targeted deletion of MMP-2 attenuates early LV rupture and late remodeling after experimental myocardial infarction. Am J Physiol Heart Circ Physiol 2003, 285:H1229-H1235.
• [58]van den Borne SW, Cleutjens JP, Hanemaaijer R, Creemers EE, Smits JF, Daemen MJ, Blankesteijn WM: Increased matrix metalloproteinase-8 and −9 activity in patients with infarct rupture after myocardial infarction. Cardiovasc Pathol 2009, 18:37-43.
• [59]George SJ: Wnt pathway: a new role in regulation of inflammation. Arterioscler Thromb Vasc Biol 2008, 28:400-402.
• [60]Kim J, Kim DW, Ha Y, Ihm MH, Kim H, Song K, Lee I: Wnt5a induces endothelial inflammation via beta-catenin-independent signaling. J Immunol 2010, 185:1274-1282.
• [61]Sen M, Ghosh G: Transcriptional outcome of Wnt-Frizzled signal transduction in inflammation: evolving concepts. J Immunol 2008, 181:4441-4445.
• [62]Kobayashi K, Luo M, Zhang Y, Wilkes DC, Ge G, Grieskamp T, Yamada C, Liu TC, Huang G, Basson CT, Kispert A, Greenspan DS, Sato TN: Secreted Frizzled-related protein 2 is a procollagen C proteinase enhancer with a role in fibrosis associated with myocardial infarction. Nat Cell Biol 2009, 11:46-55.
• [63]Matsushima K, Suyama T, Takenaka C, Nishishita N, Ikeda K, Ikada Y, Sawa Y, Jakt LM, Mori H, Kawamata S: Secreted frizzled related protein 4 reduces fibrosis scar size and ameliorates cardiac function after ischemic injury. Tissue Eng Part A 2010, 16:3329-3341.
• [64]Saraswati S, Alfaro MP, Thorne CA, Atkinson J, Lee E, Young PP: Pyrvinium, a potent small molecule Wnt inhibitor, promotes wound repair and post-MI cardiac remodeling. PLoS One 2010, 5:e15521.
• [65]Laeremans H, Hackeng TM, van Zandvoort MA, Thijssen VL, Janssen BJ, Ottenheijm HC, Smits JF, Blankesteijn WM: Blocking of frizzled signaling with a homologous peptide fragment of wnt3a/wnt5a reduces infarct expansion and prevents the development of heart failure after myocardial infarction. Circulation 2011, 124:1626-1635.
• [66]Jugdutt BI: Limiting fibrosis after myocardial infarction. New England J Med 2009, 360:1567-1569.
• [67]Angers S, Moon RT: Proximal events in Wnt signal transduction. Nat Rev Mol Cell Biol 2009, 10:468-477.
• [68]Zelarayan LC, Noack C, Sekkali B, Kmecova J, Gehrke C, Renger A, Zafiriou MP, van der Nagel R, Dietz R, de Windt LJ, Balligand JL, Bergmann MW: Beta-Catenin downregulation attenuates ischemic cardiac remodeling through enhanced resident precursor cell differentiation. Proc Natl Acad Sci USA 2008, 105:19762-19767.
• [69]Monkley SJ, Delaney SJ, Pennisi DJ, Christiansen JH, Wainwright BJ: Targeted disruption of the Wnt2 gene results in placentation defects. Development 1996, 122:3343-3353.
• [70]Ishikawa T, Tamai Y, Zorn AM, Yoshida H, Seldin MF, Nishikawa S, Taketo MM: Mouse Wnt receptor gene Fzd5 is essential for yolk sac and placental angiogenesis. Development 2001, 128:25-33.
• [71]Shu W, Jiang YQ, Lu MM, Morrisey EE: Wnt7b regulates mesenchymal proliferation and vascular development in the lung. Development 2002, 129:4831-4842.
• [72]Ye X, Wang Y, Cahill H, Yu M, Badea TC, Smallwood PM, Peachey NS, Nathans J: Norrin, frizzled-4, and Lrp5 signaling in endothelial cells controls a genetic program for retinal vascularization. Cell 2009, 139:285-298.
• [73]Blankesteijn WM, van Gijn ME, Essers-Janssen YP, Daemen MJ, Smits JF: Beta-catenin, an inducer of uncontrolled cell proliferation and migration in malignancies, is localized in the cytoplasm of vascular endothelium during neovascularization after myocardial infarction. Am J Pathol 2000, 157:877-883.
• [74]Min JK, Park H, Choi HJ, Kim Y, Pyun BJ, Agrawal V, Song BW, Jeon J, Maeng YS, Rho SS, Shim S, Chai JH, Koo BK, Hong HJ, Yun CO, Choi C, Kim YM, Hwang KC, Kwon YG: The WNT antagonist Dickkopf2 promotes angiogenesis in rodent and human endothelial cells. J Clin Invest 2011, 121:1882-1893.
• [75]Leri A, Kajstura J, Anversa P: Mechanisms of myocardial regeneration. Trends Cardiovasc Med 2011, 21:52-58.
• [76]Kajstura J, Urbanek K, Rota M, Bearzi C, Hosoda T, Bolli R, Anversa P, Leri A: Cardiac stem cells and myocardial disease. J Mol Cell Cardiol 2008, 45:505-513.
• [77]Bearzi C, Rota M, Hosoda T, Tillmanns J, Nascimbene A, De Angelis A, Yasuzawa-Amano S, Trofimova I, Siggins RW, Lecapitaine N, Cascapera S, Beltrami AP, D’Alessandro DA, Zias E, Quaini F, Urbanek K, Michler RE, Bolli R, Kajstura J, Leri A, Anversa P: Human cardiac stem cells. Proc Natl Acad Sci USA 2007, 104:14068-14073.
• [78]Assmus B, Iwasaki M, Schachinger V, Roexe T, Koyanagi M, Iekushi K, Xu Q, Tonn T, Seifried E, Liebner S, Kranert WT, Grunwald F, Dimmeler S, Zeiher AM: Acute myocardial infarction activates progenitor cells and increases Wnt signalling in the bone marrow. Eur Heart J 2012, 33:1911-1919.
• [79]Templin C, Kotlarz D, Faulhaber J, Schnabel S, Grote K, Salguero G, Luchtefeld M, Hiller KH, Jakob P, Naim HY, Schieffer B, Hilfiker-Kleiner D, Landmesser U, Limbourg FP, Drexler H: Ex vivo expanded hematopoietic progenitor cells improve cardiac function after myocardial infarction: role of beta-catenin transduction and cell dose. J Mol Cell Cardiol 2008, 45:394-403.
• [80]Pereira RF, Halford KW, O’Hara MD, Leeper DB, Sokolov BP, Pollard MD, Bagasra O, Prockop DJ: Cultured adherent cells from marrow can serve as long-lasting precursor cells for bone, cartilage, and lung in irradiated mice. Proc Natl Acad Sci USA 1995, 92:4857-4861.
• [81]Mirotsou M, Zhang Z, Deb A, Zhang L, Gnecchi M, Noiseux N, Mu H, Pachori A, Dzau V: Secreted frizzled related protein 2 (Sfrp2) is the key Akt-mesenchymal stem cell-released paracrine factor mediating myocardial survival and repair. Proc Natl Acad Sci USA 2007, 104:1643-1648.
• [82]Alfaro MP, Pagni M, Vincent A, Atkinson J, Hill MF, Cates J, Davidson JM, Rottman J, Lee E, Young PP: The Wnt modulator sFRP2 enhances mesenchymal stem cell engraftment, granulation tissue formation and myocardial repair. Proc Natl Acad Sci USA 2008, 105:18366-18371.
• [83]Sato N, Meijer L, Skaltsounis L, Greengard P, Brivanlou AH: Maintenance of pluripotency in human and mouse embryonic stem cells through activation of Wnt signaling by a pharmacological GSK-3-specific inhibitor. Nat Med 2004, 10:55-63.
• [84]Gregory CA, Singh H, Perry AS, Prockop DJ: The Wnt signaling inhibitor dickkopf-1 is required for reentry into the cell cycle of human adult stem cells from bone marrow. J Biol Chem 2003, 278:28067-28078.
• [85]Alfaro MP, Vincent A, Saraswati S, Thorne CA, Hong CC, Lee E, Young PP: sFRP2 suppression of bone morphogenic protein (BMP) and Wnt signaling mediates mesenchymal stem cell (MSC) self-renewal promoting engraftment and myocardial repair. J Biol Chem 2010, 285:35645-35653.
• [86]Oikonomopoulos A, Sereti KI, Conyers F, Bauer M, Liao A, Guan J, Crapps D, Han JK, Dong H, Bayomy AF, Fine GC, Westerman K, Biechele TL, Moon RT, Force T, Liao R: Wnt signaling exerts an antiproliferative effect on adult cardiac progenitor cells through IGFBP3. Circ Res 2011, 109:1363-1374.